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Abstract
Background: The prevalence and factors associated with overweight/obesity among human immunodeficiency virus (HIV)-
infected persons are unknown.
Methods: We evaluated prospective data from a U.S. Military HIV Natural History Study (1985–2004) consisting of early
diagnosed patients. Statistics included multivariate linear regression and longitudinal linear mixed effects models.
Results: Of 1682 patients, 2% were underweight, 37% were overweight, and 9% were obese at HIV diagnosis. Multivariate
predictorsofahigherbodymassindex(BMI)atdiagnosisincludedmorerecentyearofHIVdiagnosis,olderage,AfricanAmerican
race, and earlier HIV stage (all p,0.05). The majority of patients (62%) gained weight during HIV infection. Multivariate factors
associated with a greater increase in BMI during HIV infection included more recent year of diagnosis, lower BMI at diagnosis,
higher CD4 count, lower HIV RNA level, lack of AIDS diagnosis, and longer HIV duration (all p,0.05). Nucleoside agents were
associated with less weight gain; other drug classes had no significant impact on weight change in the HAART era.
Conclusions: HIV-infected patients are increasingly overweight/obese at diagnosis and during HIV infection. Weight gain
appears to reflect improved health status and mirror trends in the general population. Weight management programs may
be important components of HIV care.
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Introduction
Obesity rates among the general population have steadily risen
[1]; however data on weight trends among human immunodefi-
ciency virus (HIV)-infected persons are sparse. Most prior studies
have had significant limitations including their cross-sectional
study designs, lack of longitudinal weight measurements, evalua-
tion of only a single clinic setting, or their focus on wasting alone
[2–5]. However, it is likely that as HIV-infected patients are living
longer [6,7] and experiencing lower rates of acquired immuno-
deficiency syndrome (AIDS)-related wasting syndrome [8–11] due
to the beneficial effects of highly active antiretroviral therapy
(HAART), they may become overweight or obese at a rate similar
to that of the general U.S. population and suffer from medical
comorbidities related to excess weight.
No study to date has provided data on the weight trends among
HIV-infected patients over the course of the HIV epidemic. In
addition, there is a paucity of longitudinal data on the factors
associated with weight changes during the course of an individual’s
HIV infection. Therefore, we evaluated prospectively collected
data to assess weight trends during the epidemic and examined
factors associated with weight changes among individual patients
during HIV infection.
Methods
We examined prospectively collected data as part of the U.S.
Military Natural History Study, a multicenter observational study,
which enrolled 4586 HIV-infected persons from 1985–2004 at
seven U.S. geographic locations. From the total study cohort, all
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were less than 18 years of age, they did not have a baseline height
measurement recorded, or they did not have a baseline weight
measurement within one year of HIV diagnosis. Participants were
military beneficiaries (active duty, retirees, and dependents); active
duty members are HIV negative upon service entry and undergo
mandatory testing every 1–5 years. Participants are evaluated on a
biannual basis and weight measurements, medical conditions, and
medications are collected utilizing standardized collection
procedures.
Data collected at HIV diagnosis (baseline) included: weight and
height; demographics (age, gender, self-reported race/ethnicity);
military duty status; Walter Reed stage designated 1–6 for
ascending degrees of disease based on cluster of differentiation 4
(CD4) counts, opportunistic infections, lymphadenopathy, and
delayed-type hypersensitivity [12]; CD4 counts; HIV ribonucleic
acid (RNA) levels (including a category for ‘missing’ as viral loads
were not routinely collected until 1996); and medical history. Data
collected at each follow-up visit included weight, CD4 counts,
HIV RNA levels recorded as copies/milliliter (mL) by Roche,
Amplicor assay, antiretroviral therapy prescription dates, and
updated medical history. Weight measurements were obtained at
the initial evaluation and at each six-month visit; patients were
weighed on calibrated scales at each site, and measurements were
taken with patients’ clothes on. The study period was a priori
divided into two pre-HAART periods (1985–1990 and 1991–
1995) and two HAART periods (1996–2000 and 2001–2004);
since there were no significant differences in outcomes between the
two HAART periods, these were combined into 1996–2004 for
some analyses. Body mass index (BMI) at baseline and each
semiannual visit was categorized with ,18.5 kilogram per meter
squared (kg/m
2) as underweight, 18.5–24.9 kg/m
2 as normal
weight, 25–29.9 kg/m
2 as overweight, and $30 kg/m
2 as obese
[13,14]. All participants were evaluated for baseline BMI
(n=1682) and participants with $1 year of follow-up were also
evaluated longitudinally from time of HIV diagnosis to last study
visit (n=1255); the mean number of weight measurements per
participant was 9 with a standard deviation (SD) of 6. Incident
cases of becoming underweight, overweight, or obese were
confirmed by two consecutive measurements during follow-up.
All participants included in this report were diagnosed with HIV
infection from 1985 to 2004. The last weight measurement was
obtained on April 23, 2007.
Our study was approved by the central governing Institutional
Review Board which is located at Wilford Hall Medical Center,
Lackland Air Force Base, San Antonio, Texas. The study was
conducted according to the principles expressed in the Declaration
of Helsinki. All study participants provided written informed
consent.
Statistical analyses utilized Fisher’s exact tests for baseline BMI
group comparisons for categorical variables and Kruskal-Wallis
tests for continuous measurements. Predictors of BMI at baseline
were tested in univariate and multivariate linear regression
models. Least squares means (adjusted to the sample’s marginal
frequencies) were computed for predicted BMI by baseline
subgroups. The multivariate model was adjusted for age, gender,
race/ethnicity, year of HIV diagnosis, baseline CD4 count and
HIV RNA level, military duty status, and Walter Reed stage. The
multivariate model was repeated to examine the subgroup of
documented seroconverters.
Comparisons across BMI categories at the time of last visit
for the incidence (between baseline and last visit) of
hypertension, hyperlipidemia, diabetes, or heart disease
utilized Fisher’s exact tests. Patients diagnosed with the
condition prior to HIV diagnosis were excluded from these
specific analyses.
Change in BMI from baseline was computed at each follow-up
visit among participants with a BMI measurement at HIV
diagnosis and at least one weight measurement $1y e a ra f t e r
diagnosis. Using longitudinal linear mixed effects models with
random intercept and random slope across years of follow-up for
each participant, regressions for change in BMI were fitted using
all follow-up data. Factors of interest included age, gender, race/
ethnicity, baseline BMI, year of HIV diagnosis, baseline Walter
Reed stage, and time-updated variables for active duty status,
CD4 count, HIV RNA level, an AIDS-defining illness, and
cumulative time receiving antiretroviral therapy (ART). All time-
updated covariates represented the most recently observed value
at or prior to each BMI measurement. The multivariate model
was adjusted for all factors of interest, as well as for follow-up
time. Least square means (adjusted to the sample’s marginal
frequencies) were computed for predicted change in BMI over
follow-up for each categorical factor. Additional multivariate
models were performed examining: 1) the subgroup of partici-
pants diagnosed in the HAART era (since 1 Jan 1996), 2) this
subgroup before initiation of ART, and 3) this subgroup after
initiation of ART. Missing BMI values were not imputed. Results
were considered statistically significant for P-values,0.05. All
analyses were conducted using SAS (version 9.1, SAS Institute,
Cary, NC).
Results
Baseline Characteristics and Weight Measurements at HIV
Diagnosis
From the total study cohort, participants were excluded from
the current analyses if they were less than 18 years of age (n=0),
they did not have a baseline height measurement recorded
(n=419), or they did not have a baseline weight measurement
within one year of HIV diagnosis (n=2870); the later exclusion
was mainly a result of participant enrollment into the study cohort
.1 year after diagnosis. In total, 1682 participants met inclusion
criteria; this group was older (31 vs. 30 years), more likely male
(93% vs. 90%), Caucasian (51% vs. 45%), active duty (83% vs.
63%), and had earlier stage infection (66% vs. 50%) than those
excluded from the analysis (p,0.05). Of the 1682 participants,
1367 (81%) were documented HIV seroconverters with a median
seroconversion window of 16.9 months (IQR: 10.3–29.2).
Table 1 shows the baseline characteristics of the 1682
participants at HIV diagnosis. Across the entire study period
(1985–2004), at the time of HIV diagnosis, 31 (2%) were
underweight, 871 (52%) were normal weight, 623 (37%) were
overweight, and 157 (9%) were obese. The mean BMI at diagnosis
was 25.0 (SD 3.8, range from 12.3 to 45.7). Among men
(n=1556), 1% were underweight, 52% were normal weight, 38%
were overweight, and 9% were obese. Comparatively, women
(n=126) were more likely to be underweight (9%, p,0.001) and
obese (17%, p=0.006), but less likely to be overweight (24%,
p=0.002). Overall, the mean BMI of men and women was similar
(25.0 vs. 25.4, p=0.42).
Factors Associated with BMI at HIV Diagnosis
In the multivariate analysis, older age (p,0.001), African
American (p,0.001) compared to Caucasian race, early vs. late
Walter Reed stage (p,0.001), and a more recent year of HIV
diagnosis (p,0.001) were associated with a higher BMI at HIV
diagnosis (Table 2). We repeated our analyses utilizing only
Obesity in HIV Patients
PLoS ONE | www.plosone.org 2 April 2010 | Volume 5 | Issue 4 | e10106documented HIV seroconverters with similar results (data not
shown).
Changes in Weights among HIV-Infected Persons at HIV
Diagnosis over the Epidemic
Over the HIV epidemic, the percentage of participants
overweight and obese at the time of HIV diagnosis increased
(Figure 1) as did the mean BMI (Figure 2). The percentage of
participants overweight at HIV diagnosis nearly doubled from
1985–1990 (25%) to 1996–2004 (41%), while obesity increased
four-fold (3% vs. 12%, respectively). Being underweight remained
uncommon (2%) throughout the 20-year study period. Analyses
limitedto documentedHIVseroconverters producedsimilar trends.
BMI and Weight Changes among HIV-infected Persons
during the Course of their HIV Infection
Participants (n=1255) were followed for changes in weight
during their HIV infection (mean follow-up 6.2 years, SD 3.9).
This group was older (p,0.001) and consisted of fewer women
(p=0.02) than those excluded due to lack of follow-up data.
Eighty-one percent of the 1255 received antiretroviral therapy for
a mean of 4.4 years (SD 3.3) and HAART was utilized among
65% for a mean of 4.0 years (SD 2.7). The most common
antiretroviral class utilized was nucleoside reverse transcriptase
inhibitors (NRTIs) taken by 81% of participants; the most
common NRTI was zidovudine (71%), followed by lamivudine
(67%), stavudine (36%), didanosine (29%), tenofovir (21%), and
Table 1. Baseline Characteristics by Weight Category.
Weight Category
Underweight Normal Overweight Obese P*
No. 31 871 623 157
Age
Mean 6 SD 34.0613.8 29.668.8 31.068.1 32.869.0 ,.001
Gender ,.001
Male 20 (1.3%) 807 (51.9%) 593 (38.1%) 136 (8.7%)
Female 11 (8.7%) 64 (50.8%) 30 (23.8%) 21 (16.7%)
Race/Ethnicity ,.001
White/non-Hispanic/Other 22 (2.6%) 471 (55.3%) 296 (34.8%) 62 (7.3%)
African American 6 (0.8%) 348 (49.0%) 274 (38.6%) 82 (11.5%)
Hispanic/Latino 3 (2.5%) 52 (43.0%) 53 (43.8%) 13 (10.7%)
Duty Status ,.001
Active 13 (0.9%) 716 (51.3%) 543 (38.9%) 123 (8.8%)
Retired 6 (3.9%) 87 (57.2%) 47 (30.9%) 12 (7.9%)
Dependent 12 (8.9%) 68 (50.4%) 33 (24.4%) 22 (16.3%)
CD4 count (cells/mm
3) ,.001
Mean 6 SD 360.76287.4 519.36263.9 539.26266.9 487.06234.5
Median (IQR) 305.0 (180, 489) 493.0 (347, 650) 507.0 (365, 673) 477.0 (324, 637)
HIV RNA (log10 copies/mL) 0.02
Mean 6 SD 4.661.0 4.360.9 4.260.9 4.161.0
Median (IQR) 4.9 (4.5, 5.0) 4.4 (3.8, 4.9) 4.3 (3.6, 4.8) 4.3 (3.4, 4.8)
HIV RNA levels (copies/mL) 0.001
Missing 16 (51.6%) 397 (45.6%) 219 (35.2%) 55 (35.0%)
,1,000 2 (6.5%) 42 (4.8%) 53 (8.5%) 13 (8.3%)
1000–10000 0 (0.0%) 104 (11.9%) 95 (15.3%) 29 (18.5%)
10000–100000 9 (29.0%) 248 (28.5%) 192 (30.8%) 48 (30.6%)
.100000 4 (12.9%) 80 (9.2%) 64 (10.3%) 12 (7.6%)
Walter Reed stage ,.001
Stage 1 or 2 12 (1.0%) 622 (51.1%) 477 (39.2%) 106 (8.7%)
Stage 3 or 4 5 (1.8%) 135 (49.3%) 96 (35.0%) 38 (13.9%)
Stage 5 or 6 13 (6.9%) 113 (60.1%) 49 (26.1%) 13 (6.9%)
Year of HIV Diagnosis ,.001
1985–1990 7 (2.3%) 211 (69.4%) 77 (25.3%) 9 (3.0%)
1991–1995 13 (2.2%) 299 (51.0%) 219 (37.4%) 55 (9.4%)
1996–2004 11 (1.4%) 361 (45.6%) 327 (41.3%) 93 (11.7%)
*P-values represent differences in proportions between baseline BMI categories were tested using Fisher’s exact tests and differences in medians used Kruskal-Wallis
tests.
doi:10.1371/journal.pone.0010106.t001
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participants and included indinavir (24%), nelfinavir (23%),
ritonavir (22%), lopinavir (10%). Nucleoside reverse transcriptase
inhibitors (NNRTIs) were used by 44%, most commonly efavirenz
(39%). The mean CD4 count at initiation of ART was 381 cells/
mm
3 (SD 162) and 384 (SD 200) in the pre- and HAART eras,
respectively.
During the course of HIV infection, 61.5% (n=772) of patients
gained weight, 2.9% (n=36) had no weight change, and 35.6%
(n=447) lost weight. Among those who gained weight, mean
increase in BMI and weight was 2.3 kg/m
2 (SD 2.0) and 7.3 kg
(SD 5.9), respectively, from baseline to last visit. The mean BMI
and weight gain per year of follow-up was 0.55 kg/m
2/year and
1.71 kg/year, respectively. Among participants who lost weight,
the mean change in BMI and weight was 21.7 kg/m
2 (SD 1.8)
and 25.4 kg (SD 5.5), respectively (mean follow-up time 5.4
years). Of those who lost weight, the mean BMI and weight loss
was 20.48 kg/m
2/year and 21.46 kg/year of follow-up.
Among participants initially underweight at baseline, 24%
remained underweight at last visit, while 67% reached a normal
weight, 5% became overweight, and 5% became obese. Twenty-
six percent who were normal weight at baseline were overweight,
and 0.5% was obese at last visit; only 4.5% of those with normal
weight progressed to underweight at last visit. The majority of
overweight or obese participants at baseline remained in these
categories during their HIV infection, with only 1 of 609 becoming
underweight.
We also examined the incidence of changes in weight category
at anytime during follow-up. The incidence of becoming
overweight among participants initially underweight or normal
Table 2. Factors Associated with BMI at Time of HIV Diagnosis.
Univariate Models Multivariate Model
Mean ± SE Est. Diff* ± SE P* Mean ± SE Est. Diff* ± SE P*
Age
,30 24.5260.12 Referent 24.4860.12 Referent
30–39 25.7360.16 1.2160.20 ,0.001 25.6960.16 1.2160.20 ,0.001
$40 25.6760.26 1.1560.28 ,0.001 26.0960.28 1.6160.31 ,0.001
Gender
Male 25.0160.10 20.3460.35 0.32 25.0160.09 20.5460.42 0.20
Female 25.3560.33 Referent 25.5460.40 Referent
Race/Ethnicity
White/non-Hispanic/Other 24.6760.13 Referent 24.7060.13 Referent
African American 25.4160.14 0.7560.19 ,0.001 25.4160.14 0.7060.19 ,0.001
Hispanic/Latino 25.3760.34 0.7060.36 0.05 25.4160.33 0.7160.35 0.05
Duty Status
Active 25.0960.10 Referent 25.0860.10 Referent
Retired 24.2960.30 20.8060.32 0.01 24.5060.33 20.5860.35 0.10
Dependent 25.2560.32 0.1660.34 0.64 25.3660.39 0.2860.41 0.49
Year of HIV Diagnosis
1985–1990 23.5560.21 Referent 23.8960.24 Referent
1991–1995 25.0860.15 1.5360.26 ,0.001 25.1060.17 1.2160.26 ,0.001
1996–2004 25.5660.13 2.0160.25 ,0.001 25.4560.17 1.5760.33 ,0.001
CD4 at HIV Diagnosis
,500 cells/mm
3 24.9860.13 20.1560.18 0.42 24.9160.14 20.2860.21 0.18
$500 cells/mm
3 25.1260.13 Referent 25.1960.14 Referent
HIV RNA levels (copies/mL)
Missing 24.5560.14 20.5060.33 0.13 25.0360.18 0.2260.38 0.57
,1000 25.6860.36 0.6360.46 0.17 25.3460.36 0.5360.46 0.25
1000–10000 25.9160.25 0.8660.38 0.03 25.4760.25 0.6660.38 0.08
10000–100000 24.1560.17 0.1060.34 0.77 24.8960.18 0.0860.33 0.81
.100000 25.0560.29 Referent 24.8160.30 Referent
Walter Reed stage at HIV Diagnosis
Stages 1 & 2 25.1160.11 Referent 25.1560.11 Referent
Stages 3 & 4 25.4760.23 0.3660.25 0.15 25.2860.24 0.1360.28 0.64
Stages 5 & 6 23.9060.27 21.2160.29 ,0.001 24.0560.28 21.1060.31 ,0.001
*P-values indicate whether the mean BMI at baseline for groups within a factor are significantly different from that of the referent. The estimated difference represents
the difference in mean BMI at baseline between the group and the referent. For example, the estimated difference of 0.70 (p,0.001) for African American race in the
multivariate model indicates that the mean baseline BMI was 0.70 kg/m
2 higher for African American compared to White participants.
doi:10.1371/journal.pone.0010106.t002
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while the incidence of obesity among overweight participants
(n=487) was 4.3 per 100 PYs. The incidence of becoming
underweight among those with an initial BMI.18.5 kg/m
2
(n=1234) was only 0.2 per 100 PYs. With an expanded definition
to include either the development of a BMI,18.5 kg/m
2 or a
.10% loss of weight from baseline, the incidence was 1.0 per
100 PYs; however, 34% of those who lost .10% were overweight
or obese prior to weight loss.
BMI Measurements at Last Visit and Development of
Medical Conditions
At their last visit, 2.7% of HIV-infected patients were
underweight, and 56% were overweight (41.5%) or obese
(14.9%). Among participants diagnosed during the HAART era
(1996–2004, n=630), 46% were overweight, 16% were obese, and
0.6% were underweight at last visit. Women were more likely than
men to be underweight (7% vs. 2%, p=0.02) and obese (23% vs.
14%, p=0.05) at last visit; there was a trend that women were less
likely overweight (31% vs. 42%, p=0.06). Mean BMI values at
last visit for men and women were the same (26.0 kg/m
2). The
mean BMI at last visit increased over the HIV epidemic in a
similar pattern to the BMI values at HIV diagnosis.
Hypertension developed during the course of HIV infection in
0%, 6.2%, 8.6%, and 17.6% of those who were underweight,
normal weight, overweight, and obese, respectively (p,0.001).
Hyperlipidemia developed in 2.9%, 13.8%, 24.3%, and 28.8% of
the four increasing weight categories (p,0.001). Diabetes was
diagnosed in 2.9%, 3.0%, 4.8%, and 6.0% of HIV-infected
patients, respectively (p=0.22). Only six participants developed
Figure 1. Trends in Weight Categories at HIV Diagnosis during the HIV Epidemic.
doi:10.1371/journal.pone.0010106.g001
Figure 2. Trends in Mean BMI Measurements at HIV Diagnosis during the HIV Epidemic.
doi:10.1371/journal.pone.0010106.g002
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adjusting for age, race, and gender.
Factors Associated with Longitudinal Weight Trends
during HIV Infection
A repeated measures analysis was performed to identify factors
associated with changes in BMI from baseline over the course of
HIV infection (Table 3, Model 1). All factors had estimated mean
changes in BMI that were positive and significantly different from
zero (all p-values,0.001) in the multivariate model, except for
being obese at baseline (mean change =0.18, p=0.23) and
developing an AIDS diagnosis (mean change=0.03, p=0.80).
Factors associated with a greater increase in BMI in the final
multivariate model included a more recent year of HIV diagnosis:
participants diagnosed with HIV in 1985–1990 had an average
increase in BMI of 0.51 kg/m
2 compared to increases of 0.62 kg/
m
2 and 0.93 kg/m
2 for those diagnosed in 1991–1995 and 1996–
2004, respectively. Additionally, lower baseline BMI was associ-
ated with a greater increase in BMI: participants who were
underweight had an average increase in BMI of 2.92 kg/m
2, while
participants who were normal, overweight, or obese had an
average increase of 0.89 kg/m
2, 0.66 kg/m
2, or 0.18 kg/m
2,
respectively. Other factors associated with greater increases in
BMI included a higher time-updated CD4 cell count (p,0.001), a
lower time-updated HIV RNA level (all p,0.001 when compared
to level .100000 copies/mL), lack of an AIDS diagnosis
(p,0.001), and increased time since HIV infection (p,0.001).
There were no significant effects of age, gender, race, Walter Reed
stage, or active duty status on BMI changes.
Regarding antiretroviral medication use, longer cumulative
time on ART was associated with smaller increases in weight gain
(Table 3, Model 1). When considering cumulative time on
individual drug classes (instead of cumulative time on any ART
regimen), increased exposure to NRTIs was associated with
smaller increases in weight gain (p,0.001; Table 3, Model 1, last
three rows); NNRTIs and PIs were associated with greater
increases in weight gain per year of exposure, but neither was
significant in the multivariate model. As an example, a 30-year-old
white male diagnosed in 1990 with seven years of follow-up who
received both NRTIs and a PI for one year had an estimated BMI
increase of 1.23 kg/m
2 during follow-up. A person with the same
characteristics with five years of NRTI and one year of PI
exposure had an estimated increase in BMI of 0.63 kg/m
2.
Specific NRTIs, including the thymidine analogs (zidovudine and
stavudine) as well as didanosine and zalcitabine, were associated
with less weight gain, whereas the other NRTIs were not
significantly associated with weight change (data not shown).
We repeated the adjusted multivariate model for patients
diagnosed in the HAART era (n=630). Results were similar,
except that an AIDS event was not associated with less weight
gain, likely due to the small number of events in the HAART era
(data not shown). We also examined factors associated with
changes in BMI before use of antiretroviral agents among patients
diagnosed in the HAART era and found higher time-updated
CD4 count (estimate 0.25, p=0.05), lower time-updated HIV-
RNA level (HIV-RNA,1000 copies/mL vs. $100000 copies/
mL, estimate 0.58, p=0.01) and longer duration of HIV infection
(estimate 0.26, p,0.001) remained associated with greater weight
gain (data not shown). Finally, we examined participants
diagnosed in the HAART era and after initiation of HAART
(Table 3, Model 2); factors associated with more weight gain
included longer duration of HIV infection, whereas factors
associated with less weight gain included male gender, being
obese, and early stage infection (all p,0.05). Increased exposure to
NRTIs had a trend towards less weight gain. NNRTIs or PIs in
the univariate and multivariate models were not significantly
associated with weight gain. We repeated Models 1 and 2
separately by gender and found similar results.
Discussion
Our study demonstrates a high prevalence of being overweight
or obese among HIV-infected patients in the U.S. We found that
46% of persons in our HIV cohort were overweight or obese at the
time of HIV diagnosis, a percentage that steadily increased from
28% in 1985–1990 to 53% in 1996–2004. Given that our
participants were diagnosed early in the course of HIV infection
due to military testing policies, these data may be a reflection of
the growing obesity epidemic in the general population [1]. Since
U.S. HIV testing guidelines have been expanded [15], our data
provide important information about weight trends among
persons diagnosed early in infection.
Our study also demonstrated that most HIV-infected patients
are gaining weight during their infection, rather than experiencing
weight loss or becoming underweight, which characterized the
early epidemic. Among those diagnosed in the HAART era,
nearly two-thirds of HIV-infected patients were overweight or
obese at last visit. This percentage is similar to both the U.S.
general and military populations [16,17], suggesting that as HIV
has become a chronic disease, HIV-infected patients’ weights may
be normalizing to the general population. Although encouraging
in terms of the ability of antiretroviral therapy to reduce the
occurrence of end-stage disease and wasting, HIV clinicians now
need to be cognizant of weight excess among their patients.
From published data, the proportions of HIV-negative military
members who were overweight or obese in 2005 were 60% and
12%, respectively [17]. Among our cohort of HIV-infected
military beneficiaries, these proportions were 56% and 15% at
the last study visit, respectively. These data suggest that prevalence
of being overweight or obese among HIV-positive military
beneficiaries is similar to that of HIV-negative persons within
the military.
Although studies have suggested that wasting may remain
common [3,4,18], more recent studies have found that obesity was
more common than wasting [2,10]. Disparate study results may be
related to differences in timing of HIV diagnosis and treatment,
socioeconomic status, and access to medical care. Of note, our
population was diagnosed early in infection, had stable incomes,
adequate food supplies, and free access to medical care. These
data suggest that early diagnosis as supported by the recent CDC
guidelines [15] and optimized medical care may be important
factors in preventing AIDS-related wasting, which may, in turn,
improve survival [19–21].
Several factors were associated with a greater increase in BMI in
our study. Greater increase in weight gain in more recent years
was likely related to the positive effects of antiretroviral therapy on
preventing HIV-related complications, including wasting. Con-
current with this finding was that improved HIV status, as
measured by the lack of AIDS diagnosis, lower HIV RNA levels,
and high CD4 counts, was associated with increased weight gain
similar to other studies [11,22,23]. An additional reason for weight
gain may be the rising prevalence of weight excess in the general
population [1].
Lower BMI at HIV diagnosis was also linked to more weight
gain; although the exact nature of this finding is unclear, patients
who initially had more advanced disease and lower weights may
have become healthier and gained weight over time. Another
possible explanation is that HIV-infected patients who perceive
Obesity in HIV Patients
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Model 1*: Factors associated with changes in BMI
among all participants (N=1255)
Model 2*: Factors associated with changes in BMI
after initiation of ART among participants
diagnosed in the HAART Era (N=355)
Factors
Est. Mean
Change in BMI
Est. Mean Difference in
Change in BMI ± SE P
**
Est. Mean
Change in BMI
Est. Mean Difference in
Change in BMI ± SE P
**
Age
,30 0.81
{ Referent - 0.70
{ Referent -
30–39 0.70
{ 20.1160.10 0.26 0.39
{ 20.3060.17 0.07
$40 0.60
{ 20.2160.15 0.16 0.78
{ 0.0860.26 0.75
Gender
Male 0.75
{ 0.0660.19 0.75 0.54
{ 20.9660.40 0.02
Female 0.69
{ Referent - 1.50
{ Referent -
Race/Ethnicity
White/non-Hispanic/Other 0.71
{ Referent - 0.50
{ Referent -
African American 0.75
{ 0.0360.10 0.72 0.69
{ 0.1960.17 0.26
Hispanic/Latino 0.96
{ 0.2460.18 0.18 0.53
{ 0.0260.27 0.94
Active Duty (time updated)
No 0.71
{ Referent - 0.44
{ Referent -
Yes 0.77
{ 0.0560.06 0.35 0.61
{ 0.1760.17 0.32
Baseline BMI Category
Underweight 2.92
{ 2.0360.37 ,0.001 1.37
{ 0.6160.70 0.38
Normal 0.89
{ Referent - 0.76
{ Referent -
Overweight 0.66
{ 20.2360.10 0.02 0.62
{ 20.1460.17 0.42
Obese 0.18 20.7160.16 ,0.001 20.24 21.0060.24 ,0.001
Year of HIV Diagnosis
1985–1990 0.51
{ Referent - XX X
1991–1995 0.62
{ 0.1160.15 0.46 X X X
1996–2004 0.93
{ 0.4260.16 0.009 X X X
Baseline Walter Reed stage
Stage 1 or 2 0.75
{ 20.1760.17 0.32 0.51
{ 20.7060.32 0.03
Stage 3 or 4 0.65
{ 20.2660.19 0.18 0.58
{ 20.6360.33 0.06
Stage 5 or 6 0.91
{ Referent - 1.20
{ Referent -
CD4 (time updated)
,350 cells/mm
3 0.59
{ Referent - 0.44
{ Referent -
$350 cells/mm
3 0.79
{ 0.2060.04 ,0.001 0.60
{ 0.1660.10 0.10
HIV RNA levels (time updated copies/mL)
Missing 0.71
{ 0.3760.09 ,0.001 X X X
,1000 0.72
{ 0.3860.08 ,0.001 0.52 20.0160.24 0.96
1000–10000 0.88
{ 0.5360.08 ,0.001 0.78 0.2460.25 0.33
10000–100000 0.79
{ 0.4560.08 ,0.001 0.85 0.3160.25 0.21
.100000 0.34
{ Referent - 0.54 Referent -
Time from HIV Diagnosis to ART Start
(years)
XX X 20.1360.07 0.06
AIDS Diagnosis (time updated)
No 0.78
{ Referent - 0.58
{ Referent -
Yes 0.08 20.7060.12 ,0.001 0.46 20.1360.67 0.85
Time since HIV Diagnosis (years) NA 0.1760.02 ,0.001 NA 0.2860.09 0.002
Time on ART (years, time updated) NA 20.1260.02 ,0.001 X X X
Time on class-specific ART (years, time
updated)
{{
NRTIs
{{ NA 20.1560.03 ,0.001 NA 20.2360.12 0.05
PIs
{{ NA 0.0460.03 0.10 NA 0.0360.09 0.71
Obesity in HIV Patients
PLoS ONE | www.plosone.org 7 April 2010 | Volume 5 | Issue 4 | e10106that they have a low BMI may gain more weight in an attempt to
obscure their diagnosis [24]. Finally, duration of HIV was
associated with weight gain; this observation is of particular
interest, since long-term HIV infection, in the past, was associated
with being underweight, rather than weight excess.
We found no association between ART and increased weight
gain in the HAART era. In fact, antiretroviral use was associated
with less weight gain. Specifically, NRTI use (zidovudine and the
‘‘D’’ drugs) was associated with less weight gain. This finding
concurs with the lipoatrophic effects of some NRTI agents [25].
We found no significant relationships between NNRTIs or PIs and
a greater change in BMI during the HAART era in our adjusted
multivariate models. Our study did not collect information on
weight distribution; as a result, we were unable to determine if
various antiretroviral medications were related to differing
patterns of lipodystrophy.
Our study has the advantage of examining longitudinal ART
use in a clinical practice setting. Short-term studies have shown
that ART initiation leads to weight gain, but this often tapers off or
reverses over time [25–27]. Our population initiated HAART at a
mean CD4 count of 384 cells/mm
3; although HAART’s effect on
weight gain among end-stage patients may differ, our data provide
important information among those initiating HAART by the
recent treatment guidelines. Other studies on weight patterns have
also shown no clear relationship between weight and HAART
[2,5,10]. Together, these data suggest that ART may not play a
direct role in causing excess weight and that the weight gain seen
in the HAART era may be more related to improved health status
rather than to direct ART effects.
The adverse health consequences of weight excess are well-
described in the general population [28,29], but limited data exist
among HIV-infected patients. Our participants who were
overweight or obese at last visit had a higher incidence of
hypertension and hyperlipidemia. In the general population,
excess weight contributes cardiovascular disease [29] and other
medical conditions; the high rates of hyperlipidemia, hypertension,
insulin resistance, and cardiovascular disease among HIV-infected
patients [30–32] may also be partly due to excess weight. The
increasing number of these medical complications may also be
related to the use of certain antiretroviral medications, including
protease inhibitors. Beyond the health consequences, these
comorbidities impact healthcare costs; the complications associat-
ed with being overweight or obese accounts for nearly 10% of the
total U.S. medical expenditures in the general population [33].
Applying these estimated costs to HIV-infected persons [33], if
46% and 16% of the 1.1 million HIV-infected patients in the U.S.
are overweight or obese, respectively, this could result in an extra
$250 million per year of healthcare costs among HIV-infected
persons. Finally, since obesity contributes to lower life expectancies
in the general population [28,34], it is conceivable that it could
also negatively impact survival among HIV-infected patients.
These data suggest that weight management strategies are urgently
needed components of HIV care which have the potential of
reducing medical comorbidities, healthcare costs, and mortality
among HIV-infected persons [35,36].
Study limitations include the predominant male population
evaluated; although the U.S. HIV population is predominantly
male, our results cannot be generalized to women. We did,
however, perform separate analyses by gender in our cohort. Since
we evaluated a military cohort consisting of patients with early
diagnosis, stable income, access to food, and free care, some of our
results may not be generalizable to the overall HIV population and
specifically to patients diagnosed late or with limited medical
access. However, our study provides important data on weight
trends among HIV-infected persons in the setting of optimized
medical and social support. Data on physical activity, tobacco use,
family history, or diet were not available; previous studies have
shown that HIV-infected patients often ingest high fat diets, which
likely affects rates of obesity [37–39]. Another limitation of our
study is the lack of an HIV-negative control group for comparison.
Furthermore, capture of medical conditions may have changed
over time which may have limited our findings regarding these
outcomes. Finally, although BMI is a well-recognized tool for
weight assessment, it does not capture information on body
habitus and may lack accuracy in certain ethnicities including
African Americans whereby it may overestimate the prevalence of
obesity [40]. Caliper measurements to determine percent body fat
in various body sites would have been helpful in determining fat
distributions and weight assessments in this study and are often
conducted among military members; however, these data were not
available in our study database. Since BMI does not depict
changes in regional body fat distribution (i.e., central obesity) often
seen among HIV-infected persons, future studies should capture
information on body fat distribution.
In summary, HIV-infected persons in the U.S. are increasingly
overweight and obese with rates of weight excess similar to the
general population. Weight excess in the HIV-infected population
is associated with adverse medical consequences, such as
Model 1*: Factors associated with changes in BMI
among all participants (N=1255)
Model 2*: Factors associated with changes in BMI
after initiation of ART among participants
diagnosed in the HAART Era (N=355)
Factors
Est. Mean
Change in BMI
Est. Mean Difference in
Change in BMI ± SE P
**
Est. Mean
Change in BMI
Est. Mean Difference in
Change in BMI ± SE P
**
NNRTIs
{{ NA 0.0560.03 0.06 NA 0.0860.09 0.37
SE, standard error.
*Adjusted for all other variables as described in the Methods.
**p-value represents the comparison of subgroup vs. reference group for each level of the factor of interest. The estimated difference represents the difference in mean
change in BMI between the subgroup and the referent. For example, in Model 1, the estimated difference of 2.03 for participants who were underweight at baseline
indicates that the mean change in BMI was 2.03 kg/m
2 higher when compared to participants of normal weight at baseline.
{P,0.05, for comparison of mean change to zero.
{{The analyses for Model 1 were repeated, once examining ART of any type, and once examining antiretroviral classes individually. The analyses for Model 2 only
included antiretroviral classes individually.
‘‘X’’ indicates that the factor was not included in the model. ‘‘NA’’ indicates the summary was not applicable for this variable type.
doi:10.1371/journal.pone.0010106.t003
Table 3. Cont.
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these trends and consider instituting weight management pro-
grams as part of routine HIV care.
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